title: Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
abstract: The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n=5), chronic myelomonocytic leukemia (CMML) (n=8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n=7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.
authors.affiliation: Department of Blood and Marrow Transplant, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: P
authors.initials: P
authors.lastname: Mittal
authors.forename: R M
authors.initials: RM
authors.lastname: Saliba
authors.forename: S A
authors.initials: SA
authors.lastname: Giralt
authors.forename: M
authors.initials: M
authors.lastname: Shahjahan
authors.forename: A I
authors.initials: AI
authors.lastname: Cohen
authors.forename: S
authors.initials: S
authors.lastname: Karandish
authors.forename: F
authors.initials: F
authors.lastname: Onida
authors.forename: M
authors.initials: M
authors.lastname: Beran
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: M
authors.initials: M
authors.lastname: de Lima
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000628:therapy*; D015477:Leukemia, Myelomonocytic, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000628:therapy*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D016044:Fusion Proteins, bcr-abl